May 14, 2020
FDA accelerates development of COVID-19 prevention, treatment options
Editor's Note
The Food & Drug Administration on May 11 took new actions to accelerate the development of novel prevention and treatment options for COVID-19.
The agency is providing guidance documents to make the process for submitting applications to initiate studies for new drugs and biological products more efficient.
The documents also outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these products for COVID-19.
Free Daily News
- CDC communication breakdown raises public health risk
- Study: Shorter radiation schedule matches safety of standard prostate cancer treatment
- Poll: Healthcare cybersecurity leaders overlook AI-enabled physical security gaps
- ASC improves hospital efficiency, maintains outcomes despite higher-acuity joint replacement patients
- Hospital support staff cuts raise risk of infection, delays in care
- Study: Blocking stress-linked prolactin surge relieves postoperative pain in women
- Report ranks states by nursing opportunity
- Report: Hospitals double down on ASCs as outpatient shift accelerates
- Centralized waitlists slash joint replacement wait times in Canada, study shows
- Airborne bacteria pose hidden threat in cardiac ORs, study warns
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement